BioAtla, Inc. (BCAB) stock
BCABOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.31−0.05 (-3.68%)
Close on Oct 19, 2026Market cap $2.18MP/E –Yield –
BioAtla net income
Net income is the profit left for shareholders after every expense, interest and tax.
BioAtla's net income for the twelve months ending Jun 30, 2026 was -$31.45M. For fiscal 2025 it was -$59.61M. The highest annual figure on record is -$29.86M in fiscal 2019.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$59.61M | – |
| FY2024 | Dec 31, 2024 | -$69.78M | – |
| FY2023 | Dec 31, 2023 | -$123.46M | – |
| FY2022 | Dec 31, 2022 | -$106.48M | – |
| FY2021 | Dec 31, 2021 | -$95.40M | – |
| FY2020 | Dec 31, 2020 | -$35.85M | – |
| FY2019 | Dec 31, 2019 | -$29.86M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $452.00K | – |
| Q1 FY2026 | Mar 31, 2026 | -$6.34M | – |
| Q4 FY2025 | Dec 31, 2025 | -$9.78M | – |
| Q3 FY2025 | Sep 30, 2025 | -$15.78M | – |
| Q2 FY2025 | Jun 30, 2025 | -$18.71M | – |
| Q1 FY2025 | Mar 31, 2025 | -$15.33M | – |
| Q4 FY2024 | Dec 31, 2024 | -$14.88M | – |
| Q3 FY2024 | Sep 30, 2024 | -$10.59M | – |
| Q2 FY2024 | Jun 30, 2024 | -$21.07M | – |
| Q1 FY2024 | Mar 31, 2024 | -$23.23M | – |
| Q4 FY2023 | Dec 31, 2023 | -$26.93M | – |
| Q3 FY2023 | Sep 30, 2023 | -$33.33M | – |
| Q2 FY2023 | Jun 30, 2023 | -$35.75M | – |
| Q1 FY2023 | Mar 31, 2023 | -$27.46M | – |
| Q4 FY2022 | Dec 31, 2022 | -$27.54M | – |
| Q3 FY2022 | Sep 30, 2022 | -$25.78M | – |
| Q2 FY2022 | Jun 30, 2022 | -$28.91M | – |
| Q1 FY2022 | Mar 31, 2022 | -$24.25M | – |
| Q4 FY2021 | Dec 31, 2021 | -$23.39M | – |
| Q3 FY2021 | Sep 30, 2021 | -$22.93M | – |
| Q2 FY2021 | Jun 30, 2021 | -$30.38M | – |
| Q1 FY2021 | Mar 31, 2021 | -$18.70M | – |
| Q4 FY2020 | Dec 31, 2020 | -$16.40M | – |
| Q3 FY2020 | Sep 30, 2020 | -$11.63M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.22M | – |
| Q1 FY2020 | Mar 31, 2020 | -$1.60M | – |
See a number that looks wrong?